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Abstract
Background: We highlight a chronic inflammatory disease we call 'hyper-IgG4 disease', which has
many synonyms depending on the organ involved, the country of origin and the year of the report.
It is characterized histologically by a lymphoplasmacytic inflammation with IgG4-positive cells and
exuberant fibrosis, which leaves dense fibrosis on resolution. A typical example is idiopathic
retroperitoneal fibrosis, but the initial report in 2001 was of sclerosing pancreatitis.
Methods: We report an index case with fever and severe systemic disease. We have also reviewed
the histology of 11 further patients with idiopathic retroperitoneal fibrosis for evidence of IgG4-
expressing plasma cells, and examined a wide range of other inflammatory conditions and fibrotic
diseases as organ-specific controls. We have reviewed the published literature for disease
associations with idiopathic, systemic fibrosing conditions and the synonyms: pseudotumour,
myofibroblastic tumour, plasma cell granuloma, systemic fibrosis, xanthofibrogranulomatosis, and
multifocal fibrosclerosis.
Results: Histology from all 12 patients showed, to varying degrees, fibrosis, intense inflammatory
cell infiltration with lymphocytes, plasma cells, scattered neutrophils, and sometimes eosinophilic
aggregates, with venulitis and obliterative arteritis. The majority of lymphocytes were T cells that
expressed CD8 and CD4, with scattered B-cell-rich small lymphoid follicles. In all cases, there was
a significant increase in IgG4-positive plasma cells compared with controls. In two cases, biopsies
before and after steroid treatment were available, and only scattered plasma cells were seen after
treatment, none of them expressing IgG4. Review of the literature shows that although pathology
commonly appears confined to one organ, patients can have systemic symptoms and fever. In the
active period, there is an acute phase response with a high serum concentration of IgG, and during
this phase, there is a rapid clinical response to glucocorticoid steroid treatment.
Conclusion: We believe that hyper-IgG4 disease is an important condition to recognise, as the
diagnosis can be readily verified and the outcome with treatment is very good.
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Background
While investigating a patient who had an uncharacterised
multisystem disease with evidence of a severe acute-phase
response, we found that similar rare cases had been
described, usually as single reports [1], under an alarming
list of synonyms [2] (Table 1). These conditions are all
characterised by chronic inflammation leading to dense
fibrosis, and retroperitoneal fibrosis (RPF) is a typical
example. The principal synonyms that we found for these
fibrosing conditions are: pseudotumour, myofibroblastic
tumour, plasma cell granuloma, systemic fibrosis, xan-
thofibrogranulomatosis, and multifocal fibrosclerosis
(Table 1). As can be seen in Tables 1 and 2, these condi-
tions, such as RPF, Reidel's thyroiditis and sclerosing pan-
creatitis, are usually localised to one or two organs but can
present with systemic multisystem disease.
In another patient, we observed the rare behaviour of idi-
opathic RPF behaving like a tumour, in which the inflam-
matory mass was invading both the kidney and liver and
presented as a progressive cholangitis. This case was one
of a series of patients seen in our gastroenterological
department, who had sclerosing pancreatitis and chronic
inflammation associated with immunoglobulin (Ig)G4-
expressing plasma cells [3,4]. In biopsies from both these
cases, we found typical fibrosis with lymphoplasmacytic
inflammation and IgG4-bearing plasma cells [5].
Sclerosing (autoimmune) pancreatitis is a unique form of
pancreatitis, characterized by hypergammaglobulinaemia
and a lymphoplasmacytic inflammation of the pancreas
that responds to glucocorticoid treatment. It has several
synonyms (Table 2). A Japanese group investigating this
condition [6] found that the sera of their patients had a
polyclonal band in the rapidly migrating fraction of gam-
maglobulins, which was caused by a high concentration
of the IgG4 gammaglobulin fraction. They also reported
that serum concentrations of IgG4 were significantly and
specifically raised in patients with sclerosing pancreatitis,
and were closely associated with disease activity [6].
The same Japanese group found that of the 22 patients
with sclerosing pancreatitis they studied, three also had
concomitant hydronephrosis caused by a periureteric
mass, diagnosed as RPF (Ormond's disease). Histological
examination of the periureteric tissue showed abundant
infiltration of IgG4-bearing plasma cells. Treatment with
corticosteroids lowered serum concentrations of IgG4,
and the authors proposed that IgG4 might have a patho-
logical role in a systemic fibrosing process that includes
pancreatic and retroperitoneal lesions [5].
Kamisawa et al have also published several reports
emphasising the systemic nature of this process. Patients
with autoimmune pancreatitis may also have involve-
ment of lymph nodes and salivary glands as well as local
tissues [7,8], in a pattern suggestive of multifocal fibro-
sclerosis [9,10].
We describe our index case, and report on the histological
features of 11 other patients seen at our hospital with idi-
opathic RPF, for whom we have now been able to review
the histology and examine sections for evidence of IgG4-
expressing plasma cells. We also list the synonyms and
disease associations that we believe are all part of the same
disease process.
Methods
Histological examination
We report on the histological features of 16 biopsy speci-
mens from 12 patients seen at the Middlesex hospital with
a primary diagnosis of RPF, for whom we have now been
Table 1: Systemic fibrosis synonyms
Pseudotumour, inflammatory pseudotumour, 
fibrous pseudotumour
Systemic[83-85] Lung[86-89], liver[87,90-93], breast[94], pancreas[83,95-99], 
orbit[100], RPF[98-101], mesentery[102]
Inflammatory myofibroblastic tumour, 
myofibroblastoma
Systemic Pancreas[96], lung[46,103,104], brain[105], breast[106]
Plasma cell granuloma Systemic lung[107,108], brain[107]
Systemic fibrosis, generalized form of 
Ormond's disease, systemic idiopathic fibrosis, 
idiopathic systemic sclerosing disease
Systemic[1,109-111] PRF[109,111-113], orbit[112], lung[114,115]
Xanthofibrogranulomatosis, xanthogranuloma Systemic[1,2,116,117] RPF[101,118-121], brain[118,122], orbit[123]
Multifocal fibrosclerosis, multifocal idiopathic 
fibrosclerosis
Systemic[84,85,124-128] RPF[124,125,128-133], orbit[124,129-131,134] 
thyroid[127,128,132,133], pancreas[9]
RPF, retroperitoneal fibrosis.BMC Medicine 2006, 4:23 http://www.biomedcentral.com/1741-7015/4/23
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able to review the histology and examine sections for evi-
dence of IgG4-expressing plasma cells. Only archival par-
affin wax-embedded material was used for this study. All
the biopsies were taken for diagnostic reasons with the
informed consent of patients.
All the samples were routinely fixed in formalin and
embedded in paraffin wax. Dewaxed sections (μm) were
stained with haematoxylin and eosin. Immunohisto-
chemical analysis was performed using antibodies (all
Dako UK Ltd, Cambridgeshire, UK) against CD3, CD4,
CD8, CD20, and CD138, and the kappa and lambda light
chains of immunoglobulins, by the standard streptavidin-
biotin-peroxidase method. For IgG4, a mouse human
IgG4 monoclonal antibody was used (1:100 dilution,
MC011; The Binding Site, Birmingham, UK). Negative
controls were created by substituting the primary anti-
body with similarly diluted non-immunized mouse
serum.
We examined a wide variety of other inflammatory condi-
tions and fibrotic diseases as organ-specific controls,
which included liver (autoimmune hepatitis, chronic hep-
atitis C), pancreas (chronic and alcoholic pancreatitis),
salivary gland (chronic sialadenitis), gallbladder (chronic
cholecystitis), kidney (tubulointerstitial nephritis), duo-
denum (chronic duodenitis), colon (non-specific colitis),
and other fibrotic processes (Dupuytren's, keloid scars).
Because an association between RPF and asbestos expo-
sure has been reported [11], we also included cases of
malignant mesotheliomas. In addition, specimens from
cases of "benign pleural plaques" were stained as controls.
Positive controls comprised tissue obtained from pan-
creas, salivary gland and liver from patients seen in our
gastroenterological department who had sclerosing pan-
creatitis and chronic inflammation associated with IgG4-
expressing plasma cells, details of which have been
reported previously [3,4].
The degree of inflammation was assessed as severe [>100
inflammatory cells per high power field (), moderate (30–
100 cells/HPF) and mild (30–10 cells/HPF). The presence
of lymphoid-follicle formation, eosinophilic infiltration,
venulitis and obliterative arteritis (on elastic van Gieson-
stained sections) was also recorded. The number of IgG4-
Table 2: Conditions associated with systemic fibrosis
Name Synonyms
RPF Ormond's disease Systemic[109,111,113,135], 
lung[32,32,53,115,136,136,137], liver[138], 
breast, pancreas[5,139-141],
Retro-orbital tumour Fibrous pseudotumour of the orbit, Graves' 
orbitopathy
RPF[124,129-131,142-145]
Riedel's thyroiditis RPF[132,133,146-148] 
MFF[127,128,147,149,150]
Chronic sclerosing sialadenitis[151] Kuttner's tumour
Panniculitis Weber-Christian syndrome steatonecrosis, 
necrosing panniculitis
Systemic[110], RPF[135,152-155] Biliary 
cirrhosis[156], pancreas[157]
Sclerosing pancreatitis[158] Primary inflammatory pancreatitis (P)[159], 
lymphoplasmacytic sclerosing P[7,160,161], 
autoimmune P[162], sclerosing 
pancreaticocholangitis[163], pancreatic 
pseudo-tumour[95]
RPF[5,97,139,161,164,165], 
cholangitis[95,160,164,166,167], 
systemic[83,168-171] gastric ulcer[172], 
lung[173,174] panniculitis[157], 
mesentery[175]
Sclerosing cholangitis MFF[128], pancreas[92,166]
Bronchiolitis obliterans with organizing 
pneumonia
Cryptogenic organizing pneumonia, pulmonary 
hyalinizing granuloma.
Systemic[50,176], pancreas[173,174], 
liver[177], RPF[115,136,137], renal[46,136], 
mediastinum[178,179]
Benign pleural mesothelioma[180,181], 
calcifying pseudotumour[182,183]
Asbestos-related? RPF[11,26-28,32,32] peritoneum[56,184,185] 
pleura[54,55,186]
RPF, retroperitoneal fibrosis; MFF, multifocal fibrosclerosisBMC Medicine 2006, 4:23 http://www.biomedcentral.com/1741-7015/4/23
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positive cells was estimated by counting 10 HPF, and scor-
ing as follows: 0 (no IgG4 plasma cells/HPF), 1 (≤ 20
cells/HPF), 2 (20–50 cells/HPF) or 3 (≥ 50 cells/HPF)
[12]. Fibrosis was assessed as - (no fibrosis), + (mild), ++
(moderate) or +++ (severe).
Literature review
We reviewed the published literature for disease associa-
tions with idiopathic, systemic fibrosing conditions using
the following synonyms: pseudotumour, myofibroblastic
tumour, plasma cell granuloma, systemic fibrosis, xan-
thofibrogranulomatosis and multifocal fibrosclerosis. We
also looked for reports associating these conditions with
organ-specific conditions, particularly sclerosing pancrea-
titis (see Table 2 for other synonyms), RPF, Reidel's thy-
roiditis, panniculitis, Weber-Christian syndrome and
retro-orbital tumour, and with a range of autoimmune
diseases (Table 3).
Many of these reports are case reports. We have not
attempted to list every report but rather to draw up a com-
prehensive list of all possible associations with at least one
citation.
Results
Index case
A 39-year-old Moroccan steel fitter had lived in the UK for
31 years. He presented in May 2003 with abdominal pain,
weight loss, sweating, generalized lymphadenopathy, and
severe anaemia and thrombocytosis. Investigations
showed haemoglobin of 6.7 g/dL (normal range 13.0–
17.0 g/dL), platelets 1031 × 109/L (150–400 × 109/L),
erythrocyte sedimentation rate (ESR) 120 mm/h (0–15
mm/h), IgG 21.4 g/L (8.0–18.0 g/L), IgA 2.9 g/L (0.9–4.5
g/L), IgM 0.6 g/L (0.6–2.8 g/L) and C-reactive protein
(CRP) 289 mg/L (normal 0–5 mg/L). Biochemistry was
normal. Chest X-ray showed apical pleural thickening. An
intravenous urogram (IVU) showed left hydronephrosis;
an ultrasound scan (USS) confirmed this, and showed dil-
atation of the bile and pancreatic ducts and the gallblad-
der. Computed tomography (CT) showed multifocal
upper zone and patchy nodular airspace shadowing, with
right posterior pleural thickening and subcarinal lym-
phadenopathy. Biopsies of pleural, ileal and colonic tis-
sue, bone marrow, and left inguinal lymph node were all
either normal or showed reactive change. Cultures of
blood, urine and sputum were all negative. The patient
was also negative for human immunodeficiency virus
types 1 and 2, hepatitis B and C, human T-lymphotropic
virus, toxoplasmosis and treponemal disease. Mantoux
test was weakly positive, and although bronchoalveolar
lavage was smear-negative, there was one positive culture
for a mycobacterium after 3 weeks.
The patient was commenced on quadruple therapy for
tuberculosis (TB) in July 2003, for an organism that was
strongly isoniazid-resistant. The patient presented again
in November with fatigue, weight loss and fever, which
was thought to be medication-related. He was given pred-
nisolone 20 mg for 6 weeks of, taken off all TB therapy,
and after 2 months was feeling so well that he was told his
TB had been cured.
He re-presented 3 months later (March 2004) with a 6-
week history of night sweats, low-grade fever, lethargy,
weight loss, left pleuritic chest pain and axillary lymphad-
enopathy. Blood tests again showed microcytic anaemia,
and the same acute phase response. Antinuclear antibody
(ANA), antineutrophil cytoplasmic antibodies, mitochon-
drial antibodies and smooth-muscle antibodies were all
negative. CT showed many of the previous changes but
with a right hydronephrosis that was confirmed on IVU
(left hydronephrosis was no longer present). A repeat
bone-marrow biopsy, inguinal lymph node and transjug-
ular liver biopsies, endoscopy, colonoscopy, peritoneal
fluid aspiration and bone scan were all either normal or
non-specific. The patient was treated with quintuple anti-
TB therapy in order to cover his original mycobacterium
infection as well as an infection with Mycobacterium fortu-
itum that had been cultured from sputum on this occa-
sion. He was also treated with steroids, initially 60 mg of
prednisolone, tapered down to 20 mg over 3 months.
The patient was readmitted 6 months later with general-
ized abdominal pain and vomiting. He had stopped his
steroids 11 days earlier because of side effects. Investiga-
tions showed only a marked inflammatory response. CT
scan revealed no hydronephrosis, but now showed
dilated, thick-walled small bowel in the left iliac fossa.
During an exploratory laparotomy (October 2004), an
inflamed omental mass adherent to the small-bowel
mesentery was removed. Histology was reported as show-
ing only some fibrosis with a mild chronic inflammatory
cell infiltrate of lymphocytes and plasma cells. The patient
was recommenced on steroids and quadruple anti-TB
therapy.
He remained well for some months, but then presented
(March 2005) with a 6-week history of pain in the right
upper quadrant of the abdomen. His blood tests showed
the same inflammatory response and a USS showed
prominent intrahepatic ducts only. The histology of the
omental mass was reviewed and showed a large number
of IgG4-positve plasma cells throughout the fibroinflam-
matory reaction (Table 4). The patient's serum IgG con-
centration was 21.4 g/l and IgG4 2.4 (normal range 0–1.3
g/l). A diagnosis of hyper-IgG4 disease was made, all
microbial therapy was stopped, and the patient was
treated with prednisolone 20 mg/day with immediateBMC Medicine 2006, 4:23 http://www.biomedcentral.com/1741-7015/4/23
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Table 3: Rare associations with IgG4-related conditions (Case reports)
Head and neck
Submandibular gland fibrosis Pancreas[95], cholangitis[187,188], pseudotumour[189]
Parotid involvement pancreas[171]
Sjögren's syndrome Pancreas[171,190], RPF[164], BOOP[191]
Maculopathy MFF[126]
Uveitis RPF[192]
Conjunctiva Pseudotumour[86]
Hashimoto's disease, Graves' disease RPF[193]
Cardiovascular
Constrictive pericarditis RPF[194]
Heart valves RPF[20,22]
Mediastinal fibrosis RPF[194-196]
Chronic periaortitis/aneurysm RPF[197-205]
Vasculitis RPF[125,206,207]
Occlusive phlebitis MFF[149]
Intermittent claudication RPF[208]
Rheumatology
Rheumatoid arthritis BOOP[176], RPF[209]
Polymyalgia rheumatica BOOP[210]
Ankylosing spondylitis RPF[211]
Periarticular fibrosis RPF[212]
Skeletal hyperostosis RPF[213]
Dermatomyositis Pseudotumour[88], BOOP[214]
Polymyositis BOOP[191,215]
Scleroderma RPF[216]
Other autoimmune conditions
Systemic lupus erythematosus RPF[217]
Idiopathic thrombocytopenic purpura RPF[218,219]
Haemolytic anaemia Lung[220], cholangitis[221]
Central nervous system
Brain PCG[107], xanthogranuloma[118,222]
Sella MFF[124,126]
Spinal cord compression RPF[223]
Gastrointestinal
Primary biliary cirrhosis RPF[224], BOOP[176]
Mesentery RPF[112,152,175,225], pseudotumour[102,153,155]
Bladder/pelvic mass RPF[49,208,226,227]
Duodenal obstruction RPF[228,229]
Portal hypertension RPF[230]
Others
Familial multifocal fibrosclerosis Familial RPF MFF[43] RPF[42]
Proliferative crescentic glomerulonephritis, membranous 
glomerulonephritis
RPF[231] RPF[232]
Interstitial nephritis Pancreas[233]
Testicular involvement RPF[126,234]
MFF, multifocal fibrosclerosis; RPF, retroperitoneal fibrosis; BOOP, bronchiolitis obliterans with organizing pneumonia; PCG, plasma-cell 
granuloma.BMC Medicine 2006, 4:23 http://www.biomedcentral.com/1741-7015/4/23
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improvement in his illness. He remains on azathioprine
and 5 mg prednisolone.
Pathology of IgG4 disease
We reviewed the histology and examined sections for evi-
dence of IgG4-expressing plasma cells of 16 biopsies from
12 patients with a clinical diagnosis of idiopathic RPF
seen at our hospital in the past 10 years. Biopsies com-
prised nine samples of retroperitoneal tissue, two of liver,
and one each from kidney, colon and omentum. In addi-
tion, there were two further samples of retroperitoneal tis-
sue taken from two patients after steroid therapy.
The results are shown in Table 4. All patients showed, to
varying degrees, fibrosis, intense inflammatory cell infil-
tration with lymphocytes, plasma cells, scattered neu-
trophils and in some cases eosinophilic aggregates. The
majority of lymphocytes expressed CD8 and CD4 positiv-
ity (T-cell markers), with B cells present to a lesser degree
and with scattered B-cell-rich small lymphoid follicles. In
addition, we saw vasculitis affecting small veins, and evi-
dence of obliterative arteritis (Figures 1, 2, 3). In all cases,
there was a significant increase in IgG4-positive plasma
cells compared with controls (Figure 4). Even when few
plasma cells were seen (patients 10–12) the majority
expressed IgG4 (Figure 5). In two cases, biopsies before
and after steroid treatment were available; only scattered
plasma cells were seen after treatment, none of which
expressed IgG4 (Fig 3). In all of our patients, the kappa
and lambda light chains showed a polytypic pattern. We
used PCR to look for evidence of oligoclonal infiltrates for
IgH in one case (patient 1), as has been reported from
Japan [13], but found none. None of the wide range of
control sections showed significantly increased numbers
of IgG4-positive cells.
We also examined biopsy specimens from liver (two
patients), large bowel (one) and renal tissue (one). In all
of them, we found mild fibrosis and a small increase in
lymphoplasmacytic inflammatory cell infiltrate, although
IgG4-positive plasma cells were not seen in one liver
biopsy, nor in the colon biopsy (Table 4).
In summary, raised numbers of IgG4-positive plasma cells
are seen in both peritoneal and non-peritoneal tissues in
patients with hyper-IgG4 disease. The degree of IgG4-pos-
itive staining did not necessarily correlate with elevated
serum IgG. Our clinical impression was that the number
of IgG4-positive plasma cells was associated with disease
activity.
Discussion
RPF is probably the most common example of the condi-
tions associated with raised serum IgG4 and an IgG4-pos-
itive plasma cell infiltrate, which we call hyper-IgG4
diseases. The other most frequently recognised associa-
tions are sclerosing pancreatitis, Reidel's thyroiditis, retro-
orbital tumour, panniculitis, and sclerosing cholangitis
(see Table 2 for synonyms).
It is known that RPF can be associated with a similar
fibrotic process in other organs, particularly adjacent tis-
sues such as the mediastinum and pleura. Patients with
RPF can have systemic symptoms and be febrile. We used
RPF and our knowledge of its aetiology and pathogenesis
to review the potential mechanisms of IgG4 disease.
Table 4: Histopathology
Patient no., sex, age Organ Fibrosis* Lymphoplasmacytic
infiltrate†
Lymphoid follicles Venulitis Eosinophilic
component
IgG4-positive
plasma cells‡
(1) Male, 52 Kidney +++ +++ Yes No No 3
Liver ++ + No No Yes 0
(2) Male, 73 Retroperitoneum +++ +++ Yes Yes Yes 3
(3) Male, 39 Omentum + ++ Yes No No 3
(4) Male, 53 Retroperitoneum +++ +++ Yes Yes Yes 3
(5) Male, 45 Periureter +++ +++ Yes Yes No 2
(6) Female, 58 Retroperitoneum +++ +++ No Yes No 3
(7) Female, 55 Para-aortic tissue +++ +++ Yes Yes No 3
(8) Male, 47 Periureter tissue +++ + Yes Yes No 2
(9) Male, 48 Retroperitoneum +++ ++ No No No 2
(10) Male, 73 Retroperitoneum +++ +++ Yes Yes Yes 1
(11) Female, 56 Retroperitoneum +++ ++ Yes No No 1
(12) Male, 53 Liver ++ + No No No 1
Colon ++ + No No No 0
*Degree of interstitial fibrosis: +, mild; ++, moderate; +++, severe fibrosis.
†Degree of inflammation: +++ (severe), >100 inflammatory cells/HPF; ++ (moderate), 30–100 cells/HPF; + (mild), 10–30 cells/HPF
‡IgG4-positive plasma cells: 0, no IgG4 plasma cells/high power field (HPF); 1, ≤ 20 cells/HPF), 2, 20–50 cells/HPF; 3, ≥ 50 cells/HPF (criteria of Aoki 
et al [12]).BMC Medicine 2006, 4:23 http://www.biomedcentral.com/1741-7015/4/23
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Retroperitoneal disease
Idiopathic RPF generally presents in a non-specific man-
ner with malaise, fatigue, fever and weight loss [11,14-
16]. Pain in the back (lumbosacral) region, flank or lower
abdomen is most common. The pathognomonic feature
of RPF is a thick retroperitoneal fibrotic mass covering the
abdominal aorta and compressing the ureters. The process
of fibrosis can result in obstruction of the ureters and
renal failure, or signs and symptoms may be related to the
encasement or entrapment of other structures by the
inflammatory mass, such as hydrocoeles or unilateral leg
oedema. With renal involvement, severe hypertension is
common.
The disease presents typically between the ages of 50 and
70 years, and men are affected 2–3 times more commonly
than women [14]. The inflammatory nature of idiopathic
RPF is demonstrated by elevated ESR and CRP, reduced
haemoglobin and elevated gammaglobulins at presenta-
tion. An autoimmune nature is suggested by the finding of
ANA in 10–20% of cases, an occasional association with
different autoimmune diseases and good response to glu-
cocorticosteroids. In one series of RPF associated with
periaortitis, 10 of 16 patients were ANA-positive [17].
Although there are no randomised studies of treatment
for RPF, patients who present during the acute inflamma-
tory phase respond quickly to glucocorticosteroids.
Patients with late presentation and dense fibrosis will not
respond to medical treatment and surgery is often neces-
sary[11].
Causes and associations
RPF has many causes, although in about 70% of cases the
cause is unknown (idiopathic). The rest (secondary)
develop as a result of malignant disease, radiation ther-
Mesenteric mass Figure 1
Mesenteric mass. Patient 3 (index case): (a, b) fibrosis, lymphoid aggregates and plasma cells (haematoxylin and eosin (a) × 
100, (b) ×400); (c) CD138-positive plasma cells; (d) IgG4-positive plasma cells.BMC Medicine 2006, 4:23 http://www.biomedcentral.com/1741-7015/4/23
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apy, abdominal surgery, pancreatitis, retroperitoneal
haemorrhage, urine extravasation, and infections. Carci-
noid syndrome can cause systemic fibrosis [18], and RPF
has been described without metastatic tumour [19].
Drugs
RPF has also been associated with the use of several drugs,
but most commonly the ergotamine derivates, especially
methysergide [20] and, more recently, those used as
dopamine agonists to treat Parkinson's disease, such as
pergolide and cabergoline [21].
From an aetiological perspective, drugs associated with
RPF are important as they also cause fibrosis in various
other sites. Systemic fibrosis is a prominent feature of
methysergide use, with involvement of heart and lungs,
particularly heart valves [20,22]. A similar distribution of
pathology has been reported with the dopamine agonists
pergolide and cabergoline [23-25].
Of pathogenetic importance is the observation that with-
drawal of these offending drugs usually results in a rapid
improvement in symptoms, reduction in inflammatory
markers and regression of pathology [20]. Drug-induced
cases are not associated with ANA [16].
Asbestos
Recently, asbestos exposure has been proposed as a causal
factor for both pleural and retroperitoneal fibrosis [11,26-
28]. Asbestos fibres also cause interstitial lung fibrosis
(asbestosis), pleural fibrosis, pleural plaques, lung cancer,
and pleural and peritoneal mesothelioma [29]. Patients
exposed to asbestos, and particularly those with asbesto-
sis, have an increased incidence of ANA and other autoan-
tibodies, and raised levels of IgG and IgA. There is also a
correlation between the degree of immunological abnor-
mality and the likelihood of progression [30,31].
A case-control study in Finland of 43 patients with RPF
(86% of eligible cases) found that the age-standardised
incidence of RPF was 0.10 per 100000 person-years [11].
For every patient, five population-based matched controls
were selected. There was a strong association with asbes-
tos exposure. The odds ratio (OR) was 5.5 for <10 fibre-
years of asbestos exposure and 8.8 for ≤ 10 fibre-years.
Other risk factors were previous use of ergot derivates (OR
= 9.92), abdominal aortic aneurysm (OR = 6.73) and
smoking for >20 pack-years (OR = 4.73) [11].
We also saw pleural calcification in three of our patients
with RPF, in whom it was not present at the presentation
of the illness. One of those cases is included in our archi-
val review (patient 5, Table 4). This raises the question of
whether some of the pleural pathology associated with
IgG4 disease can heal with calcification as well as fibrosis
[32].
Aortitis
The relationship of aortic aneurysms with an inflamed
and thickened aortic wall, extensive periaortal inflamma-
tion and RPF is well known [33]. As the inflammatory
aneurysms of the abdominal aorta differ from RPF only in
the diameter of the inflamed aorta, it has been suggested
that both syndromes represent only variations of the same
disease, which has been named 'chronic periaortitis' [34].
RPF has been suggested as the most severe form of chronic
periaortitis [35,36]. Vasculitis of the vasa vasorum was
thought to be a factor in the aneurysmal dilatation
[34,37].
Renal biopsy Figure 2
Renal biopsy. Patient 1, showing renal involvement. (a) 
Cores of renal tissue with a conspicuous component of inter- 
and intra-tubular inflammatory cells (haematoxylin and eosin 
×100); (b) IgG4-positive plasma cells.BMC Medicine 2006, 4:23 http://www.biomedcentral.com/1741-7015/4/23
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Several observations suggest an immunological pathogen-
esis for this periaortitis. As well as the periaortal tissue, the
media and adventitia of the aorta are infiltrated by poly-
clonal B lymphocytes, activated CD4-positive T lym-
phocytes, and plasma cells [35]. In 85% of patients, the
necrotic media contains deposits of IgG antibodies in
close proximity to extracellular ceroid, and the serum
often contains antibodies against ceroid and oxidised
low-density lipoprotein [38].
Although it was initially proposed that the aortitis was
caused by an autoimmune response to the components of
atherosclerotic plaques [38] with antibodies to atheroma,
more recent opinion has suggested that in view of the
accompanying systemic symptoms and acute phase
response, the aortitis is a primary autoimmune disease
[17,36,39,40].
Autoimmune and other rare associations
While there is no one predominant association, a large
range of autoimmune diseases has been described in asso-
ciation with RPF (Table 3), and 10–20% of cases will have
ANA or other autoantibodies.
Paediatric
RPF in the paediatric population is rare with, only 23 cases
reported in the English-language literature by 2003 [41].
A family has been reported in which two children had idi-
opathic retroperitoneal fibrosis, and they and their father
had clinical and laboratory evidence of systemic immuno-
logical diseases [42].
Familial
Two brothers from a first-cousin consanguineous mar-
riage were reported, who had different combinations of
Retroperitoneal tissue Figure 3
Retroperitoneal tissue. Patient 7. Pre-glucocorticoid treatment: (a) fibrosis and plasma cells (haematoxylin and eosin ×400); 
(b) IgG4-positive plasma cells. Post-glucocorticoid treatment: (c) scattered CD138-positive plasma cells; (d) IgG4 staining 
reveals no positive cells.BMC Medicine 2006, 4:23 http://www.biomedcentral.com/1741-7015/4/23
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RPF, mediastinal fibrosis, sclerosing cholangitis, Riedel
sclerosing thyroiditis, and pseudotumour of the orbit.
One of the brothers had fibrotic contracture of the fingers
[43]. Other reports are of RPF in three siblings with sickle-
cell trait [44], and mediastinal and retroperitoneal fibrosis
in two sisters with seronegative spondyloarthropathy
[45].
RPF invading adjacent organs
Rarely, the inflammatory tissue seen in RPF can invade the
renal parenchyma [46-48] and it can occasionally cause a
tumour-like mass away from the retroperitoneum [49].
There are four isolated surgical case reports in the litera-
ture, with two being described as idiopathic RPF, one as
systemic hyalinizing granuloma and the other as xanthofi-
brogranuloma. We have seen one case in which the IgG4-
positive inflammatory mass (Figure 2) invaded the kidney
and liver (patient 1, Table 4), and another in which it
caused a large tumour like mass in the left iliac fossa
(patient 2). Both cases responded promptly to steroids.
Summary
Although all our archival cases of idiopathic RPF have
shown evidence of IgG4 involvement, it remains to be
seen whether IgG4 plays any role in other types of RPF
such as periaortitis, drug-induced and asbestos-related
RPF. We certainly found it (in retroperitoneal tissue) in
one of our patients who developed pleural calcification.
Histopathology: IgG4 immunostaining (cases versus controls) Figure 4
Histopathology: IgG4 immunostaining (cases versus controls). Vertical axis (0–120) shows number of IgG4-positive 
plasma cells/high power field (see Methods for details). Histological data from salivary gland is positive control, (from previ-
ously reported study [3,4]).
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Lung disease
Part of the spectrum of disease in patients with hyper-
IgG4 disease is parenchymal lung pathology, often
described as either bronchiolitis obliterans with organiz-
ing pneumonia or cryptogenic organizing pneumonia
[50]. This is seen typically as migratory pulmonary infil-
trates, and is steroid-responsive. Nevertheless, there are at
present no studies that have looked for evidence of IgG4
plasma cells in these conditions [51]. Other conditions
associated with migratory pulmonary infiltrates that may
be related, but not yet investigated, include pulmonary
eosinophilia, hypersensitivity to drugs, parasitic infection,
allergic bronchopulmonary aspergillosis and Churg-
Strauss vasculitis [52]. Pleural thickening, with and with-
out calcification, is well described [32,32,53]. There are
also reports of calcifying pseudo-tumour of the pleura
[54,55] and peritoneum [56].
Differential diagnosis of febrile illness
Fever of unknown origin (FUO) in an immunocompetent
patient is defined as an illness of more than 3 weeks' dura-
tion with fever higher than 38.3°C (101°F) on several
occasions, and with an uncertain diagnosis after 1 week of
investigation [57]. Infection accounts for about one-third
of cases (25–32%) of FUO, followed by non-infectious
inflammatory disease (21–31%) and neoplasm (12–
17%) [58-62]. Although many patients with FUO will be
found to have bacterial infection, rarer diagnoses will be
considered with time and extensive investigation. Never-
theless, at the end of all investigations, 18–30% of
Percentage of IgG4-bearing plasma cells Figure 5
Percentage of IgG4-bearing plasma cells.
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patients will have no diagnosis, although the majority of
this idiopathic group will improve spontaneously [60].
We propose that hyper-IgG4 disease can be added to this
list of systemic inflammatory diseases.
Pathogenesis
Conditions associated with elevated IgG4
IgG4 is the rarest of the IgG subclasses to be expressed,
accounting for only 3–6% of total IgG in normal serum. It
has a low affinity for target antigen. It is unique among the
IgG subclasses, as it is unable to bind Clq complement
and cannot activate the classic complement pathway [63].
IgG4 is a T-helper 2 (Th2)-dependent isotype. Interleukin
(IL)-4 directs naive human B cells to switch to IgG4 and
IgE production [64]; IL-10 and IL-13 are the other T-cell-
derived cytokines that activate this differentiation.
High serum IgG4 concentrations are found in a limited
number of other conditions, including atopic dermatitis
[65], some parasitic diseases (helminthic diseases) [66],
and pemphigus vulgaris (PV) and pemphigus foliaceus
(PF)[67,68].
In allergic individuals, a feature of successful immuno-
therapy is the induction of allergen-specific IgG4 antibod-
ies, even with the persistence of allergen-specific IgE
[69,70]. High levels of the immunosuppressive cytokine
IL-10 are found both in patients chronically infected with
helminths and in those receiving allergen immuno-
therapy [71]. IL-10 also stimulates IgG4 production [72].
Th2 responses to allergens are suppressed by both CD4+
CD25+ T regulatory cells (Tregs) and IL-10-producing
Tregs [73], and suppression by these subsets is decreased
in allergic individuals. In animal models, Tregs can be
induced by high- or low-dose inhaled antigen, and prior
induction of Tregs prevents subsequent development of
allergen sensitization and airway inflammation in inhaled
challenge models. Allergen-injection immunotherapy
may induce IL-10 Tregs, leading to both suppression of
Th2 responses and a switch from IgE to IgG4 antibody
production [73].
Helminths
Asymptomatic infections with helminth parasites are cor-
related with high levels of IgG4, and parasite-specific IgG4
antibodies can inhibit IgE-mediated degranulation of
mast cells [66]. In most helminth infections, the Th2
response leads to rapid parasite expulsion or sequestra-
tion. During murine Schistosoma mansoni infection, how-
ever, parasites persist and the chronic Th2 response can
induce severe pathological fibrosis in the gut and liver
[74]. Evidence both from these mouse models and from
human studies suggests that this progression to severe dis-
ease with intense fibrosis occurs in only a minority of
cases, and is a consequence of the strongly profibrotic type
2 cytokine response mediated by IL-4 and IL-13 [74].
Pemphigus and pemphigoid
PV and PF are autoimmune skin diseases caused by
autoantibodies against desmoglein 3 and desmoglein 1
respectively. These antibodies are predominantly of the
IgG4 subclass [67,68]. Desmogleins are keratinocyte
transmembrane proteins localized in the desmosome,
and are members of the adhesion molecule family of cad-
herins. The interaction of antidesmoglein antibodies with
their target antigens leads to loss of cell adhesion (acan-
tholysis) and the formation of intraepithelial blisters of
the skin and mucous membranes. The antibodies pre-
dominantly, but not exclusively, bind to the extracellular
domains of the proteins and exert their pathogenic effect
not through inhibition of the proteins' adhesive proper-
ties, but through an indirect pathway involving cellular
signalling pathways, resulting in destabilization of des-
moglein 1-based adhesive sites and desmosomes [75].
Bullous pemphigoid (BP) is an autoimmune blistering
disease associated with autoantibodies against the
hemidesmosomal glycoprotein BP180. The noncollagen-
ous (NC)16A domain of BP180 has major antigenic sites
recognized by BP sera. IgG4 and IgE are the major immu-
noglobulins that preferentially react with two distinct
epitopes within this domain. Levels of these autoantibod-
ies correlated with disease activity in BP [76].
Autoimmune pancreatitis
In sclerosing pancreatitis, evidence had been reported to
suggest an immunological pathogenesis even before the
description of a role for IgG4. In one study of 17 patients,
ANA and antilactoferrin antibodies were detected in 76%,
carbonic anhydrase II antibody in 59%, rheumatoid fac-
tor in 29% and anti-smooth-muscle antibody in 18% of
patients. CD8+ and CD4+ cells were significantly
increased in peripheral blood. CD4+ cells produced
increased levels of interferon gamma compared with con-
trols, but IL-4 was not increased [77]. However, in another
Japanese study, which divided patients with sclerosing
pancreatitis into a seronegative and seropositive group,
found no differences in presentation, pathology or natural
history between the groups [78].
HLA associations with IgG4-associated diseases
￿ PV was consistently found to be associated with DR4
and DR14 and, more precisely, with DRB1*0402 and
DRB1*1401 subtypes [79]. Susceptibility to PF has been
correlated with the presence of DR4, DR14 and DR1 alle-
les; however, in contrast to PV, no single DR4 or DR14
allele was shown to be associated with the disease.BMC Medicine 2006, 4:23 http://www.biomedcentral.com/1741-7015/4/23
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￿ In an immunogenetic study of patients with autoim-
mune pancreatitis, a significant increase in DR4 was
found. It was concluded that the DRB1*0405-
DQB1*0401 haplotype was associated with autoimmune
pancreatitis in the Japanese population [80].
￿ Aortoarteritis is a chronic inflammatory disease, mainly
affecting the aorta and its major branches. In a Chinese
Han population, the DRB1*04 and DRB1*07 alleles were
significantly associated with aortoarteritis. Furthermore,
there was no significant difference in the frequency of the
DRB1*0405 subtype between the patient and control
groups [81].
￿ In China, the HLA-DRB5*0101 allele and the IL-13 pro-
moter A/A genotype were both found to be elevated in
schistosomal hepatic fibrosis, although the two genes are
located on different chromosomes. Subjects with both
genotypes had odds ratios much higher (OR = 24.5) than
the sum of the ratios for each individual genotype. The
study strongly suggested that a pathogenic Th2 response
directly influenced the prognosis of post-schistosomal
liver fibrosis[82].
Conclusion
We believe that hyper-IgG4 disease is an important condi-
tion to recognise as the diagnosis can be verified by histol-
ogy and simple blood tests, and the outcome with
treatment during the acute phase is very good. A raised
IgG concentration in the absence of hypergammaglobuli-
naemia is typical, but ideally IgG4 should also be meas-
ured. Even when pathology appears localised, as with
RPF, constitutional symptoms can be present with evi-
dence of an acute phase response. Rarely a systemic form
of the disease will present with severe constitutional
symptoms, and hyper-IgG4 disease can be added to list of
unusual causes of FUO. Although the role and relevance
of IgG4 is unknown, the dense fibrosis that accompanies
healing would appear to be a typical example of Th2-
mediated pathology.
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
GH Neild was involved with clinical management of the
patients and was responsible for the writing of the paper.
Manuel Rodriguez-Justo reviewed and examined all the
histological material and helped to write the paper. Cath-
erine Wall and John O Connolly were both involved with
the clinical management of the index case and several of
the patients with RPF, and helped to write the paper.
Acknowledgements
We thank Ms P Munson for performing IgG4 immunostaining. We thank 
Drs Robin Woolfson and Helen Lachmann for reading the manuscript and 
making valuable contributions to its preparation. We would like to thank 
our colleagues Dr FD Thompson, Dr MA Mansell, Dr RG Woolfson and Dr 
BR Leaker for their help with the management of patients. Written consent 
was obtained from the patient for publication of the case history.
References
1. Streuli R, Egger C, Truniger B: Systemic fibrosis (generalized
xanthofibrogranulomatosis).  Nephrol Dial Transplant 1997,
12:608-609.
2. Kastendieck H, Husselmann H: [Xanthofibrogranulomatosis.
Classification, localization, morphology, pathogenesis]
(author's translation).  Virchows Arch A Pathol Anat Histol 1978,
380:237-259.
3. Webster GJ, Wittman J, Seward E, Pereira SP, Hatfield AR: Autoim-
mune pancreatitis/choliopancreatopathy – evidence of mult-
isystem involvement [abstract 048].  Gut 2006, 54:a1-117.
4. Deheragoda MG, Church NI, Rodriguez-Justo M, Seward E, Novelli
MR, Pereira S, Hatfield ARW, Webster GJM: IgG4 immunostain-
ing in autoimmune pancreatitis and in extra-pancreatic dis-
ease [abstract].  Pancreatology 2006, 6:193.
5. Hamano H, Kawa S, Ochi Y, Unno H, Shiba N, Wajiki M, Nakazawa
K, Shimojo H, Kiyosawa K: Hydronephrosis associated with ret-
roperitoneal fibrosis and sclerosing pancreatitis.  Lancet 2002,
359:1403-1404.
6. Hamano H, Kawa S, Horiuchi A, Unno H, Furuya N, Akamatsu T,
Fukushima M, Nikaido T, Nakayama K, Usuda N, Kiyosawa K: High
serum IgG4 concentrations in patients with sclerosing pan-
creatitis.  N Engl J Med 2001, 344:732-738.
7. Kamisawa T, Funata N, Hayashi Y: Lymphoplasmacytic sclerosing
pancreatitis is a pancreatic lesion of IgG4-related systemic
disease.  Am J Surg Pathol 2004, 28:1114.
8. Kamisawa T, Nakajima H, Egawa N, Funata N, Tsuruta K, Okamoto
A: IgG4-related sclerosing disease incorporating sclerosing
pancreatitis, cholangitis, sialadenitis and retroperitoneal
fibrosis with lymphadenopathy.  Pancreatology 2006, 6:132-137.
9. Kamisawa T, Funata N, Hayashi Y, Tsuruta K, Okamoto A, Amemiya
K, Egawa N, Nakajima H: Close relationship between autoim-
mune pancreatitis and multifocal fibrosclerosis.  Gut 2003,
52:683-687.
10. Kamisawa T: IgG4-related sclerosing disease.  Intern Med 2006,
45:125-126.
11. Uibu T, Oksa P, Auvinen A, Honkanen E, Metsarinne K, Saha H, Uitti
J, Roto P: Asbestos exposure as a risk factor for retroperito-
neal fibrosis.  Lancet 2004, 363:1422-1426.
12. Aoki S, Nakazawa T, Ohara H, Sano H, Nakao H, Joh T, Murase T,
Eimoto T, Itoh M: Immunohistochemical study of autoimmune
pancreatitis using anti-IgG4 antibody and patients' sera.  His-
topathology 2005, 47:147-158.
13. Oshiro H, Ebihara Y, Serizawa H, Shimizu T, Teshima S, Kuroda M,
Kudo M: Idiopathic retroperitoneal fibrosis associated with
immunohematological abnormalities.  Am J Med 2005,
118:782-786.
14. Baker LR, Mallinson WJ, Gregory MC, Menzies EA, Cattell WR, Whit-
field HN, Hendry WF, Wickham JE, Joekes AM: Idiopathic retro-
peritoneal fibrosis. A retrospective analysis of 60 cases.  Br J
Urol 1987, 60:497-503.
15. Yaqoob MM, Junaid I: The patient with urinary tract obstruc-
tion.  In Oxford Textbook of Clinical Nephrology Edited by: Davison AM,
Cameron JS, Grunfeld J-P, Ponticelli C, Ritz E, Winearls CG, et al.
Oxford: Oxford University Press; 2005:2465-2470. 
16. van Bommel EF: Retroperitoneal fibrosis.  Neth J Med 2002,
60:231-242.
17. Vaglio A, Corradi D, Manenti L, Ferretti S, Garini G, Buzio C: Evi-
dence of autoimmunity in chronic periaortitis: a prospective
study.  Am J Med 2003, 114:454-462.
18. Modlin IM, Shapiro MD, Kidd M: Carcinoid tumors and fibrosis:
an association with no explanation.  Am J Gastroenterol 2004,
99:2466-2478.
19. Chander S, Ergun EL, Chugani HT, Chugani DC, Juhasz C, Shields AF,
Weaver DW: High 2-deoxy-2-[18F]fluoro-D-glucose accumu-BMC Medicine 2006, 4:23 http://www.biomedcentral.com/1741-7015/4/23
Page 14 of 18
(page number not for citation purposes)
lation in a case of retroperitoneal fibrosis following resection
of carcinoid tumor.  Mol Imaging Biol 2002, 4:363-368.
20. Graham JR, Suby HI, LeCompte PR, Sadowsky NL: Fibrotic disor-
ders associated with methysergide therapy for headache.  N
Engl J Med 1966, 274:359-368.
21. Shaunak S, Wilkins A, Pilling JB, Dick DJ: Pericardial, retroperito-
neal, and pleural fibrosis induced by pergolide.  J Neurol Neuro-
surg Psychiatry 1999, 66:79-81.
22. Graham JR: Cardiac and pulmonary fibrosis during methy-
sergide therapy for headache.  Am J Med Sci 1967, 254:1-12.
23. Horvath J, Fross RD, Kleiner-Fisman G, Lerch R, Stalder H, Liaudat S,
Raskoff WJ, Flachsbart KD, Rakowski H, Pache JC, Burkhard PR, Lang
AE: Severe multivalvular heart disease: a new complication
of the ergot derivative dopamine agonists.  Mov Disord 2004,
19:656-662.
24. Bleumink GS, Molen-Eijgenraam M, Strijbos JH, Sanwikarja S, van Pui-
jenbroek EP, Stricker BH: Pergolide-induced pleuropulmonary
fibrosis.  Clin Neuropharmacol 2002, 25:290-293.
25. Pritchett AM, Morrison JF, Edwards WD, Schaff HV, Connolly HM,
Espinosa RE: Valvular heart disease in patients taking per-
golide.  Mayo Clin Proc 2002, 77:1280-1286.
26. Maguire GP, Meggs LG, Addonizio J, Del Guercio LR: Association of
asbestos exposure, retroperitoneal fibrosis, and acute renal
failure.  N Y State J Med 1991, 91:357-359.
27. Boulard JC, Hanslik T, Doleris LM, Prinseau J, Baglin A: Asbestos
and idiopathic retroperitoneal fibrosis.  Lancet 1995, 345:1379.
28. Sauni R, Oksa P, Jarvenpaa R, Parker JE, Roto P: Asbestos expo-
sure: a potential cause of retroperitoneal fibrosis.  Am J Ind
Med 1998, 33:418-421.
29. Manning CB, Vallyathan V, Mossman BT: Diseases caused by
asbestos: mechanisms of injury and disease development.  Int
Immunopharmacol 2002, 2:191-200.
30. Nigam SK, Suthar AM, Patel MM, Karnik AB, Dave SK, Kashyap SK,
Venkaiah K: Humoral immunological profile of workers
exposed to asbestos in asbestos mines.  Indian J Med Res 1993,
98:274-277.
31. Pfau JC, Sentissi JJ, Weller G, Putnam EA: Assessment of autoim-
mune responses associated with asbestos exposure in Libby,
Montana, USA.  Environ Health Perspect 2005, 113:25-30.
32. Nishi K, Myou S, Ooka T, Fujimura M, Matsuda T: A case of pleural
involvement followed by idiopathic retroperitoneal fibrosis.
Nihon Kyobu Shikkan Gakkai Zasshi 1993, 31:876-880.
33. Walker DI, Bloor K, Williams G, Gillie I: Inflammatory aneurysms
of the abdominal aorta.  Br J Surg 1972, 59:609-614.
34. Mitchinson MJ: Chronic periaortitis and periarteritis.  Histopa-
thology 1984, 8:589-600.
35. Parums DV, Dunn DC, Dixon AK, Mitchinson MJ: Characterization
of inflammatory cells in a patient with chronic periaortitis.
Am J Cardiovasc Pathol 1990, 3:121-129.
36. Vaglio A, Salvarani C, Buzio C: Retroperitoneal fibrosis.  Lancet
2006, 367:241-251.
37. Lindell OI, Sariola HV, Lehtonen TA: The occurrence of vasculitis
in perianeurysmal fibrosis.  J Urol 1987, 138:727-729.
38. Parums DV, Brown DL, Mitchinson MJ: Serum antibodies to oxi-
dized low-density lipoprotein and ceroid in chronic periaor-
titis.  Arch Pathol Lab Med 1990, 114:383-387.
39. Vaglio A, Buzio C: Chronic periaortitis: a spectrum of diseases.
Curr Opin Rheumatol 2005, 17:34-40.
40. Moroni G, Del Papa N, Moronetti LM, Vitali C, Maglione W, Comina
DP, Urgnani F, Sandri S, Ponticelli C, Cortelezzi A: Increased levels
of circulating endothelial cells in chronic periaortitis as a
marker of active disease.  Kidney Int 2005, 68:562-568.
41. Miller OF, Smith LJ, Ferrara EX, McAleer IM, Kaplan GW: Presenta-
tion of idiopathic retroperitoneal fibrosis in the pediatric
population.  J Pediatr Surg 2003, 38:1685-1688.
42. Doolin EJ, Goldstein H, Kessler B, Vinocur C, Marchildon MB: Famil-
ial retroperitoneal fibrosis.  J Pediatr Surg 1987, 22:1092-1094.
43. Comings DE, Skubi KB, Van Eyes J, Motulsky AG: Familial multifo-
cal fibrosclerosis. Findings suggesting that retroperitoneal
fibrosis, mediastinal fibrosis, sclerosing cholangitis, Riedel's
thyroiditis, and pseudotumor of the orbit may be different
manifestations of a single disease.  Ann Intern Med 1967,
66:884-892.
44. Phills JA, Geggie P, Hidvegi RI, Oliva LA: Retroperitoneal fibrosis
in three siblings with the sickle cell trait.  Can Med Assoc J 1973,
108:1025-1029.
45. Goldbach P, Mohsenifar Z, Salick AI: Familial mediastinal fibrosis
associated with seronegative spondylarthropathy.  Arthritis
Rheum 1983, 26:221-225.
46. Chalaoui J, Gregoire P, Sylvestre J, Lefebvre R, Amyot R: Pulmonary
hyalinizing granuloma: a cause of pulmonary nodules.  Radiol-
ogy 1984, 152:23-26.
47. Kell HH, Schumann HJ: Retroperitoneal xanthofibrogranuloma
simulating kidney tumor.  Zentralbl Chir 1973, 98:968-971.
48. Kohler HP, Laeng RH, Egger C, Streuli R: Systemic fibrosis (gen-
eralized form of Ormond's disease). Report of a case which
achieved complete remission with cyclophosphamide and
corticosteroids.  Schweiz Med Wochenschr 1995, 125:2131-2136.
49. Takashima T, Onoda N, Ishikawa T, Koyama T, Inaba M, Nishizawa Y,
Nakatani T, Wakasa K, Hirakawa K: Tumor-forming idiopathic
retroperitoneal fibrosis: report of a case.  Surg Today 2004,
34:374-378.
50. Duvic C, Desrame J, Leveque C, Nedelec G: Retroperitoneal
fibrosis, sclerosing pancreatitis and bronchiolitis obliterans
with organizing pneumonia.  Nephrol Dial Transplant 2004,
19:2397-2399.
51. Hirano K, Kawabe T, Komatsu Y, Matsubara S, Togawa O, Arizumi T,
Yamamoto N, Nakai Y, Sasahira N, Tsujino T, Toda N, Isayama H,
Tada M, Omata M: High-rate pulmonary involvement in
autoimmune pancreatitis.  Intern Med J 2006, 36:58-61.
52. King TE Jr: BOOP: an important cause of migratory pulmo-
nary infiltrates?  Eur Respir J 1995, 8:193-195.
53. Shimizu T, Furuichi S, Takahashi N, Koya Y, Akashiba T, Horie T: [A
case of intrathoracic extension of retroperitoneal fibrosis].
Nihon Kokyuki Gakkai Zasshi 2001, 39:748-752.
54. Ammar A, El Hammami S, Horchani H, Sellami N, Kilani T: Calcifying
fibrous pseudotumor of the pleura: a rare location.  Ann Thorac
Surg 2003, 76:2081-2082.
55. Cavazza A, Gelli MC, Agostini L, Sgarbi G, De Marco L, Gardini G:
Calcified pseudotumor of the pleura: description of a case.
Pathologica 2002, 94:201-205.
56. Kocova L, Michal M, Sulc M, Zamecnik M: Calcifying fibrous pseu-
dotumour of visceral peritoneum.  Histopathology 1997,
31:182-184.
57. Petersdorf RG, Beeson PB: Fever of unexplained origin: report
on 100 cases.  Medicine (Baltimore) 1961, 40:1-30.
58. de Kleijn EM, Vandenbroucke JP, van der Meer JW: Fever of
unknown origin (FUO). I A. prospective multicenter study of
167 patients with FUO, using fixed epidemiologic entry cri-
teria. The Netherlands FUO Study Group.  Medicine (Baltimore)
1997, 76:392-400.
59. Knockaert DC, Vanneste LJ, Bobbaers HJ: Fever of unknown ori-
gin in elderly patients.  J Am Geriatr Soc 1993, 41:1187-1192.
60. Mourad O, Palda V, Detsky AS: A comprehensive evidence-
based approach to fever of unknown origin.  Arch Intern Med
2003, 163:545-551.
61. Zhiyong Z, Bingjun L, Xiaoju L, Xinjian F, Ping F, Wenya W: Fever of
unknown origin: a report from China of 208 cases.  Int J Clin
Pract 2003, 57:592-596.
62. Bleeker-Rovers CP, de Kleijn EM, Corstens FH, van der Meer JW,
Oyen WJ: Clinical value of FDG PET in patients with fever of
unknown origin and patients suspected of focal infection or
inflammation.  Eur J Nucl Med Mol Imaging 2004, 31:29-37.
63. Van der Zee JS, van Swieten P, Aalberse RC: Inhibition of comple-
ment activation by IgG4 antibodies.  Clin Exp Immunol 1986,
64:415-422.
64. Punnonen J, Aversa G, Cocks BG, McKenzie AN, Menon S, Zurawski
G, de Waal MR, de Vries JE: Interleukin 13 induces interleukin 4-
independent IgG4 and IgE synthesis and CD23 expression by
human B cells.  Proc Natl Acad Sci U S A 1993, 90:3730-3734.
65. Aalberse RC, Van Milligen F, Tan KY, Stapel SO: Allergen-specific
IgG4 in atopic disease.  Allergy 1993, 48:559-569.
66. Hussain R, Poindexter RW, Ottesen EA: Control of allergic reac-
tivity in human filariasis. Predominant localization of block-
ing antibody to the IgG4 subclass.  J Immunol 1992,
148:2731-2737.
67. Jones CC, Hamilton RG, Jordon RE: Subclass distribution of
human IgG autoantibodies in pemphigus.  J Clin Immunol 1988,
8:43-49.
68. Futei Y, Amagai M, Ishii K, Kuroda-Kinoshita K, Ohya K, Nishikawa T:
Predominant IgG4 subclass in autoantibodies of pemphigus
vulgaris and foliaceus.  J Dermatol Sci 2001, 26:55-61.BMC Medicine 2006, 4:23 http://www.biomedcentral.com/1741-7015/4/23
Page 15 of 18
(page number not for citation purposes)
69. Ebner C, Siemann U, Bohle B, Willheim M, Wiedermann U, Schenk S,
Klotz F, Ebner H, Kraft D, Scheiner O: Immunological changes
during specific immunotherapy of grass pollen allergy:
reduced lymphoproliferative responses to allergen and shift
from TH2 to TH1 in T-cell clones specific for Phl p 1, a major
grass pollen allergen.  Clin Exp Allergy 1997, 27:1007-1015.
70. Platts-Mills T, Vaughan J, Squillace S, Woodfolk J, Sporik R: Sensiti-
sation, asthma, and a modified Th2 response in children
exposed to cat allergen: a population-based cross-sectional
study.  Lancet 2001, 357:752-756.
71. Akdis CA, Blesken T, Akdis M, Wuthrich B, Blaser K: Role of inter-
leukin 10 in specific immunotherapy.  J Clin Invest 1998,
102:98-106.
72. Jeannin P, Lecoanet S, Delneste Y, Gauchat JF, Bonnefoy JY: IgE ver-
sus IgG4 production can be differentially regulated by IL-10.
J Immunol 1998, 160:3555-3561.
73. Robinson DS, Larche M, Durham SR: Tregs and allergic disease.  J
Clin Invest 2004, 114:1389-1397.
74. Ramalingam TR, Reiman RM, Wynn TA: Exploiting worm and
allergy models to understand Th2 cytokine biology.  Curr Opin
Allergy Clin Immunol 2005, 5:392-398.
75. Waschke J, Bruggeman P, Baumgartner W, Zillikens D, Drenckhahn
D: Pemphigus foliaceus IgG causes dissociation of desmo-
glein 1-containing junctions without blocking desmoglein 1
transinteraction.  J Clin Invest 2005, 115:3157-3165.
76. Dopp R, Schmidt E, Chimanovitch I, Leverkus M, Brocker EB, Zillikens
D: IgG4 and IgE are the major immunoglobulins targeting
the NC16A domain of BP180 in bullous pemphigoid: serum
levels of these immunoglobulins reflect disease activity.  J Am
Acad Dermatol 2000, 42:577-583.
77. Okazaki K, Uchida K, Ohana M, Nakase H, Uose S, Inai M, Matsushima
Y, Katamura K, Ohmori K, Chiba T: Autoimmune-related pan-
creatitis is associated with autoantibodies and a Th1/Th2-
type cellular immune response.  Gastroenterology 2000,
118:573-581.
78. Wakabayashi T, Kawaura Y, Satomura Y, Urabe T, Watanabe H,
Motoo Y, Sawabu N: Duct-narrowing chronic pancreatitis with-
out immunoserologic abnormality: comparison with duct-
narrowing chronic pancreatitis with positive serological evi-
dence and its clinical management.  Dig Dis Sci 2005,
50:1414-1421.
79. Tron F, Gilbert D, Mouquet H, Joly P, Drouot L, Makni S, Masmoudi
H, Charron D, Zitouni M, Loiseau P, Ben Ayed M: Genetic factors
in pemphigus.  J Autoimmun 2005, 24:319-328.
80. Kawa S, Ota M, Yoshizawa K, Horiuchi A, Hamano H, Ochi Y,
Nakayama K, Tokutake Y, Katsuyama Y, Saito S, Hasebe O, Kiyosawa
K: HLA DRB10405-DQB10401 haplotype is associated with
autoimmune pancreatitis in the Japanese population.  Gastro-
enterology 2002, 122:1264-1269.
81. Dang A, Wang B, Zhang Y, Zhang P, Huang J, Liu G, Zheng D, Qiu C,
Liu L: Association of the HLA-DRB1 gene with susceptibility
to aortoarteritis in a Chinese Han population.  Hypertens Res
2002, 25:631-634.
82. Hirayama K: Immunogenetic analysis of post-schistosomal
liver fibrosis.  Parasitol Int 2004, 53:193-196.
83. Voss SD, Kruskal JB, Kane RA: Chronic inflammatory pseudotu-
mor arising in the hepatobiliary-pancreatic system: progres-
sive multisystemic organ involvement in four patients.  AJR
Am J Roentgenol 1999, 173:1049-1054.
84. van der Vliet HJ, Perenboom RM: Multiple pseudotumors in
IgG4-associated multifocal systemic fibrosis.  Ann Intern Med
2004, 141:896-897.
85. Clark A, Zeman RK, Choyke PL, White EM, Burrell MI, Grant EG,
Jaffe MH: Pancreatic pseudotumors associated with multifo-
cal idiopathic fibrosclerosis.  Gastrointest Radiol 1988, 13:30-32.
86. Goto Y, Ohaki Y, Ibaraki N: A clinicopathologic case report of
inflammatory pseudotumors involving the conjunctiva and
lung.  Jpn J Ophthalmol 2004, 48:573-577.
87. Hosler GA, Steinberg DM, Sheth S, Hamper UM, Erozan YS, Ali SZ:
Inflammatory pseudotumor: a diagnostic dilemma in
cytopathology.  Diagn Cytopathol 2004, 31:267-270.
88. Alam M, Morehead RS, Weinstein MH: Dermatomyositis as a
presentation of pulmonary inflammatory pseudotumor
(myofibroblastic tumor).  Chest 2000, 117:1793-1795.
89. Tuncozgur B, Ustunsoy H, Bakir K, Ucak R, Elbeyli L: Inflammatory
pseudotumor of the lung.  Thorac Cardiovasc Surg 2000,
48:112-113.
90. Uetsuji S, Nakagawa A, Kwon AH, Komada H, Imamura A, Kamiyama
Y: Inflammatory pseudotumor of the liver: report of a case
and review of the literature.  Surg Today 1996, 26:517-521.
91. Sato Y, Harada K, Nakanuma Y: Hepatic inflammatory pseudo-
tumour related to autoimmune pancreatitis.  Histopathology
2004, 45:418-419.
92. Zen Y, Harada K, Sasaki M, Sato Y, Tsuneyama K, Haratake J, Kuru-
maya H, Katayanagi K, Masuda S, Niwa H, Morimoto H, Miwa A, Uch-
iyama A, Portmann BC, Nakanuma Y: IgG4-related sclerosing
cholangitis with and without hepatic inflammatory pseudo-
tumor, and sclerosing pancreatitis-associated sclerosing
cholangitis: do they belong to a spectrum of sclerosing pan-
creatitis?  Am J Surg Pathol 2004, 28:1193-1203.
93. Spivach A, Turoldo A, Pistan V, Colautti I, Zanconati F: Inflamma-
tory pseudotumour of the liver: case report and review of
the literature.  Chir Ital 2005, 57:229-237.
94. Zen Y, Kasahara Y, Horita K, Miyayama S, Miura S, Kitagawa S, Naka-
numa Y: Inflammatory pseudotumor of the breast in a patient
with a high serum IgG4 level: histologic similarity to scleros-
ing pancreatitis.  Am J Surg Pathol 2005, 29:275-278.
95. Toosi MN, Heathcote J: Pancreatic pseudotumor with scleros-
ing pancreato-cholangitis: is this a systemic disease?  Am J Gas-
troenterol 2004, 99:377-382.
96. Esposito I, Bergmann F, Penzel R, di Mola FF, Shrikhande S, Buchler
MW, Friess H, Otto HF: Oligoclonal T-cell populations in an
inflammatory pseudotumor of the pancreas possibly related
to autoimmune pancreatitis: an immunohistochemical and
molecular analysis.  Virchows Arch 2004, 444:119-126.
97. Chutaputti A, Burrell MI, Boyer JL: Pseudotumor of the pancreas
associated with retroperitoneal fibrosis: a dramatic response
to corticosteroid therapy.  Am J Gastroenterol 1995, 90:1155-1158.
98. Zhao MF, Tian Y, Guo KJ, Ma ZG, Liao HH: Common bile duct
obstruction due to fibrous pseudotumor of pancreas associ-
ated with retroperitoneal fibrosis: a case report.  World J Gas-
troenterol 2004, 10:3078-3079.
99. Wiesner W, Kocher T, Beglinger C, Harder F, Steinbrich W: Pseu-
dotumor of the pancreatic head associated with idiopathic
retroperitoneal fibrosis.  Dig Surg 2001, 18:418-421.
100. Van Hoe L, Oyen R, Gryspeerdt S, Baert AL, Bobbaers H, Baert L:
Case report: pseudotumoral pelvic retroperitoneal fibrosis
associated with orbital fibrosis.  Br J Radiol 1995, 68:421-423.
101. Kondo T, Onitsuka S, Kobayashi H, Ryoji O, Toma H: A case of ret-
roperitoneal pseudotumor (xanthogranuloma).  Hinyokika Kiyo
1998, 44:21-24.
102. Ruiz-Cabello JM, Martinez Salmeron JF, Perez MJ, Salinas C, Rodrigo
MM: Inflammatory mesenteric pseudotumor.  Rev Esp Enferm
Apar Dig 1988, 73:311-314.
103. Sakurai H, Hasegawa T, Watanabe S, Suzuki K, Asamura H, Tsuchiya
R: Inflammatory myofibroblastic tumor of the lung.  Eur J Car-
diothorac Surg 2004, 25:155-159.
104. Berman M, Georghiou GP, Schonfeld T, Feinmesser M, Horev G,
Vidne BA, Saute M: Pulmonary inflammatory myofibroblastic
tumor invading the left atrium.  Ann Thorac Surg 2003,
76:601-603.
105. Jeon YK, Chang KH, Suh YL, Jung HW, Park SH: Inflammatory
myofibroblastic tumor of the central nervous system: clin-
icopathologic analysis of 10 cases.  J Neuropathol Exp Neurol 2005,
64:254-259.
106. Ilvan S, Celik V, Paksoy M, Cetinaslan I, Calay Z: Inflammatory
myofibroblastic tumor (inflammatory pseudotumor) of the
breast.  APMIS 2005, 113:66-69.
107. Greiner C, Rickert CH, Mollmann FT, Rieger B, Semik M, Heindel W,
Wassmann H: Plasma cell granuloma involving the brain and
the lung.  Acta Neurochir (Wien) 2003, 145:1127-1131.
108. Urschel JD, Horan TA, Unruh HW: Plasma cell granuloma of the
lung.  J Thorac Cardiovasc Surg 1992, 104:870-875.
109. Stewart TW Jr, Friberg TR: Idiopathic retroperitoneal fibrosis
with diffuse involvement: further evidence of systemic idio-
pathic fibrosis.  South Med J 1984, 77:1185-1187.
110. Mitchinson MJ: Systemic idiopathic fibrosis and systemic
Weber-Christian disease.  J Clin Pathol 1965, 18:645-649.BMC Medicine 2006, 4:23 http://www.biomedcentral.com/1741-7015/4/23
Page 16 of 18
(page number not for citation purposes)
111. Morad N, Strongwater SL, Eypper S, Woda BA: Idiopathic retro-
peritoneal and mediastinal fibrosis mimicking connective tis-
sue disease.  Am J Med 1987, 82:363-366.
112. Binder SC, Deterling RA Jr, Mahoney SA, Patterson JF, Wolfe HJ: Sys-
temic idiopathic fibrosis. Report of a case of the concomitant
occurrence of retractile mesenteritis and retroperitoneal
fibrosis.  Am J Surg 1972, 124:422-430.
113. Hershkowitz M, Fogari R, Chandra M: Idiopathic retroperitoneal
fibrosis: implications for a systemic disorder.  Clin Exp Rheuma-
tol 1983, 1:157-160.
114. Nakamura Y, Kohzaki S, Suyama N, Yamaguchi T, Kohno S, Hayashi
K: Systemic idiopathic fibrosis with inflammatory pulmonary
lesions.  Br J Radiol 1997, 70:956-958.
115. Kuramochi S, Kawai T, Yakumaru K, Mikata A, Torikata C, Kasuga Y,
Fujiwara T: Multiple pulmonary hyalinizing granulomas associ-
ated with systemic idiopathic fibrosis.  Acta Pathol Jpn 1991,
41:375-382.
116. Kastendieck H: Xanthofibrogranulomatosis – a tumor-like
lesion of the intestinal adipose tissue with a tendency
towards generalization.  Verh Dtsch Ges Pathol 1978, 62(501):501.
117. Miyachi S, Kobayashi T, Takahashi T, Saito K, Hashizume Y, Sugita K:
An intracranial mass lesion in systemic xanthogranulomato-
sis: case report.  Neurosurgery 1990, 27:822-826.
118. Grunow N, Goertchen R: Generalized retroperitoneal xan-
thofibrogranulomatosis with brain involvement.  Pathologe
1988, 9:305-308.
119. Verswijvel G, Stragier J, Verhelle J, Roskams T, Oyen RH: Bilateral
xanthogranulomatous perinephritis without renal parenchy-
mal involvement.  Eur Radiol 2000, 10:900-902.
120. Arvis G, de Boisgisson P, Schrameck E: Retroperitoneal xan-
thogranuloma. Apropos of 4 cases.  J Urol Nephrol (Paris) 1975,
81:550-557.
121. Forster R, Ruschoff J, Kleinsorge F: Retroperitoneal xanthofibro-
granulomatosis.  Rofo 1989, 151:688-691.
122. Dauch WA, Rossberg C, Luttges J: Xanthofibrogranulomatosis
with meningocortical involvement.  Zentralbl Allg Pathol 1986,
132:33-36.
123. Malhotra R, Porter RG, Selva D: Adult orbital xanthogranuloma
with periosteal infiltration.  Br J Ophthalmol 2003, 87:120-121.
124. van der PR, Nieuwenhuis MG, Mourits MP: Multifocal fibrosclero-
sis presenting as Grave's orbitopathy. Bilateral exophthal-
mos associated with retroperitoneal and sellar fibrosis.
Graefes Arch Clin Exp Ophthalmol 1999, 237:256-258.
125. Schnitzler L, Verret JL, Caron C, Tuchais E, Soret JY, Salaun Y:
[Multifocal fibrosclerosis (retroperitoneal, mediastinal,
mesenteric and pelvic involvement) associated with vasculi-
tis and revealed by a livedo: clinical, histopathological and
ultrastructural study in a case] (author's translation).  Ann
Dermatol Venereol 1978, 105:943-956.
126. Brazier DJ, Sanders MD: Multifocal fibrosclerosis associated
with suprasellar and macular lesions.  Br J Ophthalmol 1983,
67:292-296.
127. Tutuncu NB, Erbas T, Bayraktar M, Gedik O: Multifocal idiopathic
fibrosclerosis manifesting with Riedel's thyroiditis.  Endocr
Pract 2000, 6:447-449.
128. Laitt RD, Hubscher SG, Buckels JA, Darby S, Elias E: Sclerosing
cholangitis associated with multifocal fibrosis: a case report.
Gut 1992, 33:1430-1432.
129. Manassero A, Cracco C, Terrone C, Rossetti SR: Coexistence of
orbital and retroperitoneal involvement in multifocal fibro-
sclerosis: case report.  Arch Ital Urol Androl 1998, 70:11-14.
130. Richards AB, Shalka HW, Roberts FJ, Flint A: Pseudotumor of the
orbit and retroperitoneal fibrosis. A form of multifocal fibro-
sclerosis.  Arch Ophthalmol 1980, 98:1617-1620.
131. Levine MR, Kaye L, Mair S, Bates J: Multifocal fibrosclerosis.
Report of a case of bilateral idiopathic sclerosing pseudotu-
mor and retroperitoneal fibrosis.  Arch Ophthalmol 1993,
111:841-843.
132. Meijer S, Hoitsma HF, Scholtmeijer R: Idiopathic retroperitoneal
fibrosis in multifocal fibrosclerosis.  Eur Urol 1976, 2:258-260.
133. Nielson HK: Multifocal idiopathic fibrosclerosis. Two cases
with simultaneous occurrence of retroperitoneal fibrosis
and Riedel's thyroiditis.  Acta Med Scand 1980, 208:119-123.
134. Aylward GW, Sullivan TJ, Garner A, Moseley I, Wright JE: Orbital
involvement in multifocal fibrosclerosis.  Br J Ophthalmol 1995,
79:246-249.
135. Bonnet C, Arnaud M, Bertin P, Treves R, Gotteron RD: Idiopathic
retroperitoneal fibrosis with systemic manifestations.  J Rheu-
matol 1994, 21:360-362.
136. Hashimoto S, Fujii W, Takahashi T, Shiroshita K, Sakurai T, Ueda T,
Kawata T: Pulmonary hyalinizing granuloma with hydroneph-
rosis.  Intern Med 2002, 41:463-466.
137. Dent RG, Godden DJ, Stovin PG, Stark JE: Pulmonary hyalinising
granuloma in association with retroperitoneal fibrosis.  Tho-
rax 1983, 38:955-956.
138. Dejaco C, Ferenci P, Schober E, Kaserer K, Fugger R, Novacek G,
Gangl A: Stenosis of the common bile duct due to Ormond's
disease: case report and review of the literature.  J Hepatol
1999, 31:156-159.
139. Kamisawa T, Matsukawa M, Ohkawa M: Autoimmune pancreati-
tis associated with retroperitoneal fibrosis.  JOP 2005,
6:260-263.
140. Pereira-Lima JC, Kromer MU, Adamek HE, Riemann JF: Cholestatic
jaundice due to Ormond's disease (primary retroperitoneal
fibrosis).  Hepatogastroenterology 1996, 43:992-994.
141. Cappell MS: Obstructive jaundice due to retroperitoneal
fibrosis involving the head of the pancreas.  J Clin Gastroenterol
1994, 18:53-56.
142. Fruh D, Jaeger W, Kafer O: Orbital involvement in retroperito-
neal fibrosis (morbus Ormond).  Mod Probl Ophthalmol 1975,
14(651–6):651-656.
143. Lenhard V, Bommer J, Andrassy K, Krampien B, Orth H, Ritz E:
Retro-orbital fibrosis in Ormond's disease (author's transl).
Dtsch Med Wochenschr 1974, 99:2289-2286.
144. Schonder AA, Clift RC, Brophy JW, Dane LW: Bilateral recurrent
orbital inflammation associated with retroperitoneal fibro-
sclerosis.  Br J Ophthalmol 1985, 69:783-787.
145. Reittner P, Riepl T, Goritschnig T, Preidler KW, Koele W, Szolar DH:
Bilateral orbital pseudotumour due to Ormond's disease:
MR imaging and CT findings.  Neuroradiology 2002, 44:272-274.
146. Kruit WH, den Ottolander GJ: Riedel's thyroiditis in a patient
with retroperitoneal fibrosis.  Neth J Med 1991, 39:17-19.
147. Miro I, Bakir R, Chanu B, Brocheriou C, Brenot F, Rouffy J: Riedel's
thyroiditis and retroperitoneal fibrosis. Apropos of a case of
multiple fibrosing disease.  Ann Med Interne (Paris) 1984,
135:212-216.
148. Rao CR, Ferguson GC, Kyle VN: Retroperitoneal fibrosis associ-
ated with Riedel's struma.  Can Med Assoc J 1973, 108:1019-1021.
149. Meyer S, Hausman R: Occlusive phlebitis in multifocal fibroscle-
rosis.  Am J Clin Pathol 1976, 65:274-283.
150. Wich M, Steegmuller KW, Junginger T, Teifke A: Riedel's thyroidi-
tis and idiopathic multifocal fibrosclerosis. A case report.
Chirurg 1991, 62:211-213.
151. Kitagawa S, Zen Y, Harada K, Sasaki M, Sato Y, Minato H, Watanabe
K, Kurumaya H, Katayanagi K, Masuda S, Niwa H, Tsuneyama K, Saito
K, Haratake J, Takagawa K, Nakanuma Y: Abundant IgG4-Positive
plasma cell infiltration characterizes chronic sclerosing sia-
ladenitis (Kuttner's Tumor).  Am J Surg Pathol 2005, 29:783-791.
152. Leger L, Roberti A, Deloche dN, Lemaigre G: Mesenteric pannicu-
litis, a variety of retroperitoneal fibrosclerosis.  Presse Med
1967, 75:75-79.
153. Godquin B, Saout R, Loupias P, Garipuy A, Blanchard J: Inflamma-
tory and necrotic pseudotumor of the mesentery. Classifica-
tion of mesenteric panniculitis.  J Chir (Paris) 1972, 104:167-175.
154. Paraf A, Menager C, Texier J: Mesenteric panniculitis, retroperi-
toneal lipodistrophy and pancreatic diseases. Apropos of a
case.  Presse Med 1968, 76:2263-2265.
155. Decker GA, Gaylis H: Mesenteric panniculitis simulating an
abdominal aortic aneurysm.  S Afr Med J 1972, 46:750.
156. Herr W, Lohse AW, Spahn TW, Dienes HP, Trautmann F, Meyer zum
Buschenfelde KH, Marker-Hermann E: Nodular nonsuppurative
panniculitis in association with primary biliary cirrhosis and
Hashimoto's thyroiditis.  Z Rheumatol 1996, 55:122-126.
157. Proenca NG, Frucchi H: Weber-Christian febrile recurrent
nodular nonsuppurative panniculitis and panniculitis caused
by pancreopathy: differential diagnosis and enzymatic mech-
anisms.  Rev Paul Med 1978, 91:82-83.
158. Motoo Y, Minamoto T, Watanabe H, Sakai J, Okai T, Sawabu N: Scle-
rosing pancreatitis showing rapidly progressive changes with
recurrent mass formation.  Int J Pancreatol 1997, 21:85-90.BMC Medicine 2006, 4:23 http://www.biomedcentral.com/1741-7015/4/23
Page 17 of 18
(page number not for citation purposes)
159. Sarles H, Sarles J, Muratore R, Guien C: Chronic inflammatory
sclerosis of the pancreas – an autonomous pancreatic dis-
ease?  Am J Dig Dis 1961, 6:688-698.
160. Kawaguchi K, Koike M, Tsuruta K, Okamoto A, Tabata I, Fujita N:
Lymphoplasmacytic sclerosing pancreatitis with cholangitis:
a variant of primary sclerosing cholangitis extensively involv-
ing pancreas.  Hum Pathol 1991, 22:387-395.
161. Notohara K, Burgart LJ, Yadav D, Chari S, Smyrk TC: Idiopathic
chronic pancreatitis with periductal lymphoplasmacytic infil-
tration: clinicopathologic features of 35 cases.  Am J Surg Pathol
2003, 27:1119-1127.
162. Ito T, Nakano I, Koyanagi S, Miyahara T, Migita Y, Ogoshi K, Sakai H,
Matsunaga S, Yasuda O, Sumii T, Nawata H: Autoimmune pancre-
atitis as a new clinical entity. Three cases of autoimmune
pancreatitis with effective steroid therapy.  Dig Dis Sci 1997,
42:1458-1468.
163. Erkelens GW, Vleggaar FP, Lesterhuis W, van Buuren HR, van der
Werf SD: Sclerosing pancreato-cholangitis responsive to ster-
oid therapy.  Lancet 1999, 354:43-44.
164. Fukui T, Okazaki K, Yoshizawa H, Ohashi S, Tamaki H, Kawasaki K,
Matsuura M, Asada M, Nakase H, Nakashima Y, Nishio A, Chiba T: A
case of autoimmune pancreatitis associated with sclerosing
cholangitis, retroperitoneal fibrosis and Sjogren's syndrome.
Pancreatology 2005, 5:86-91.
165. Fukukura Y, Fujiyoshi F, Nakamura F, Hamada H, Nakajo M: Autoim-
mune pancreatitis associated with idiopathic retroperito-
neal fibrosis.  AJR Am J Roentgenol 2003, 181:993-995.
166. Ichimura T, Kondo S, Ambo Y, Hirano S, Ohmi M, Okushiba S, Mori-
kawa T, Shimizu M, Katoh H: Primary sclerosing cholangitis
associated with autoimmune pancreatitis.  Hepatogastroenterol-
ogy 2002, 49:1221-1224.
167. Nishino T, Toki F, Oyama H, Oi I, Kobayashi M, Takasaki K, Shiratori
K:  Biliary tract involvement in autoimmune pancreatitis.
Pancreas 2005, 30:76-82.
168. Kamisawa T: IgG4-positive plasma cells specifically infiltrate
various organs in autoimmune pancreatitis.  Pancreas 2004,
29:167-168.
169. Kamisawa T, Funata N, Hayashi Y, Eishi Y, Koike M, Tsuruta K,
Okamoto A, Egawa N, Nakajima H: A new clinicopathological
entity of IgG4-related autoimmune disease.  J Gastroenterol
2003, 38:982-984.
170. Uchida K, Okazaki K, Konishi Y, Ohana M, Takakuwa H, Hajiro K,
Chiba T: Clinical analysis of autoimmune-related pancreatitis.
Am J Gastroenterol 2000, 95:2788-2794.
171. Pickartz T, Pickartz H, Lochs H, Ockenga J: Overlap syndrome of
autoimmune pancreatitis and cholangitis associated with
secondary Sjogren's syndrome.  Eur J Gastroenterol Hepatol 2004,
16:1295-1299.
172. Shinji A, Sano K, Hamano H, Unno H, Fukushima M, Nakamura N,
Akamatsu T, Kawa S, Kiyosawa K: Autoimmune pancreatitis is
closely associated with gastric ulcer presenting with abun-
dant IgG4-bearing plasma cell infiltration.  Gastrointest Endosc
2004, 59:506-511.
173. Taniguchi T, Ko M, Seko S, Nishida O, Inoue F, Kobayashi H, Saiga T,
Okamoto M, Fukuse T: Interstitial pneumonia associated with
autoimmune pancreatitis.  Gut 2004, 53:770-771.
174. Arai K, Kawamura O, Naruse I, Tsunekawa K, Hayashi A, Yonezu M,
Oya N, Takagi H, Mori M, Kon Y: A case of chronic pancreatitis
with diffuse irregular narrowing of the pancreatic duct com-
plicated by Sjogren's syndrome and interstitial pneumonia.
Nippon Shokakibyo Gakkai Zasshi 2001, 98:847-852.
175. Phillips RH, Carr RA, Preston R, Pereira SP, Wilkinson ML, O'Donnell
PJ, Thompson RP: Sclerosing mesenteritis involving the pan-
creas: two cases of a rare cause of abdominal mass mimick-
ing malignancy.  Eur J Gastroenterol Hepatol 1999, 11:1323-1329.
176. Harada M, Hashimoto O, Kumemura H, Taniguchi E, Shiratsuchi M,
Harada R, Sakamoto M, Yoshida H, Fukuda T, Sakisaka S, Sata M:
Bronchiolitis obliterans organizing pneumonia in a patient
with primary biliary cirrhosis and rheumatoid arthritis
treated with prednisolone.  Hepatol Res 2002, 23:301.
177. Takahashi K, Sakamoto N, Okada M, Tamechika Y, Ishibashi H:
[Interstitial pneumonia observed during acute exacerbation
of autoimmune hepatitis].  Nippon Shokakibyo Gakkai Zasshi 2000,
97:719-722.
178. Yousem SA, Hochholzer L: Pulmonary hyalinizing granuloma.
Am J Clin Pathol 1987, 87:1-6.
179. Gossot D, Fromont G, Galetta D, Debrosse D, Grunenwald D: Pul-
monary hyalinising granuloma with mediastinal fibrosis: a
rare cause of dysphagia.  Ann Chir 2003, 128:622-625.
180. Burrig KF, Kastendieck H: Ultrastructural observations on the
histogenesis of localized fibrous tumours of the pleura
(benign mesothelioma).  Virchows Arch A Pathol Anat Histopathol
1984, 403:413-424.
181. Burrig KF, Kastendieck H, Husselmann H: Localized fibrous pleu-
ral tumor (benign mesothelioma). Clinico-pathological
study of 24 cases for classification, morphogenesis and prog-
nosis.  Pathologe 1983, 4:120-129.
182. Lee HY, Chuah KL, Tan PH: Test and teach. Number fifty-three.
Diagnosis: Calcifying fibrous pseudotumour.  Pathology 2003,
35:166-169.
183. Dargent JL, Delplace J, Roufosse C, Laget JP, Lespagnard L: Develop-
ment of a calcifying fibrous pseudotumour within a lesion of
Castleman disease, hyaline-vascular subtype.  J Clin Pathol 1999,
52:547-549.
184. Zamecnik M, Boudova L, Sulc M, Michal M: Location of calcifying
fibrous pseudotumour: peritoneal predominance.  Histopathol-
ogy 2005, 46:346.
185. Weynand B, Draguet AP, Bernard P, Marbaix E, Galant C: Calcifying
fibrous pseudotumour: first case report in the peritoneum
with immunostaining for CD34.  Histopathology 1999, 34:86-87.
186. Peachell M, Mayo J, Kalloger S, Flint J, English J: Calcifying fibrous
pseudotumour of the lung.  Thorax 2003, 58:1018-1019.
187. Tsuneyama K, Saito K, Ruebner BH, Konishi I, Nakanuma Y, Gersh-
win ME: Immunological similarities between primary scleros-
ing cholangitis and chronic sclerosing sialadenitis: report of
the overlapping of these two autoimmune diseases.  Dig Dis Sci
2000, 45:366-372.
188. Sjogren I, Wengle B, Korsgren M: Primary sclerosing cholangitis
associated with fibrosis of the submandibular glands and the
pancreas.  Acta Med Scand 1979, 205:139-141.
189. Monteil RA, Saint-Paul MC, Hofman P, Jehl-Pietri C, Michiels JF,
Raspaldo H: Oral inflammatory pseudotumour: immunohisto-
chemical investigation of a case involving the submandibular
gland and review of the literature.  Oral Oncol 1997, 33:215-219.
190. Zamboni G, Luttges J, Capelli P, Frulloni L, Cavallini G, Pederzoli P,
Leins A, Longnecker D, Kloppel G: Histopathological features of
diagnostic and clinical relevance in autoimmune pancreati-
tis: a study on 53 resection specimens and 9 biopsy speci-
mens.  Virchows Arch 2004, 445:552-563.
191. Imasaki T, Yoshii A, Tanaka S, Ogura T, Ishikawa A, Takahashi T: Pol-
ymyositis and Sjogren's syndrome associated with bronchi-
olitis obliterans organizing pneumonia.  Intern Med 1996,
35:231-235.
192. Doi M, Uji Y: A case of uveitis associated with idiopathic ret-
roperitoneal fibrosis.  Am J Ophthalmol 1994, 117:358-362.
193. Armigliato M, Paolini R, Bianchini E, Monesi G, Zamboni S, D'Andrea
E:  Hashimoto's thyroiditis and Graves' disease associated
with retroperitoneal fibrosis.  Thyroid 2002, 12:829-831.
194. Hanley PC, Shub C, Lie JT: Constrictive pericarditis associated
with combined idiopathic retroperitoneal and mediastinal
fibrosis.  Mayo Clin Proc 1984, 59:300-304.
195. van Bommel EF, Bouvy ND, Liem E, Boeve ER, Weimar W: Coexist-
ent idiopathic retroperitoneal and mediastinal fibrosis pre-
senting with portal hypertension.  Neth J Med 1994, 44:174-177.
196. Morgan AD, Loughridge LW, Calne RY: Combined mediastinal
and retroperitoneal fibrosis.  Lancet 1966, 1:67-70.
197. Mitchinson MJ, Wight DG, Arno J, Milstein BB: Chronic coronary
periarteritis in two patients with chronic periaortitis.  J Clin
Pathol 1984, 37:32-36.
198. Keith DS, Larson TS: Idiopathic retroperitoneal fibrosis.  J Am
Soc Nephrol 1993, 3:1748-1752.
199. Debrand-Passard A, Wilhelm H: Ormond's disease or aortic
aneurysm? Case reports.  Int Urol Nephrol 1996, 28:295-304.
200. Vaideeswar P, Shenoy AS, Sivaraman A, Deshpande JR, Pandit AA: Idi-
opathic retroperitoneal fibrosis: a report of 3 cases.  J Postgrad
Med 1993, 39:95-98.
201. Remedios D, Coppen M, Bradbeer J, Theodossi A: Chronic peri-
aortitis presenting as common bile duct obstruction.  Gut
1991, 32:713-714.
202. Zdrojewski Z: Retroperitoneal fibrosis and chronic peri-aorti-
tis – new hypothesis.  Pol Merkuriusz Lek 1998, 4:50-53.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Medicine 2006, 4:23 http://www.biomedcentral.com/1741-7015/4/23
Page 18 of 18
(page number not for citation purposes)
203. Turo AJ, Torres LJ, Peiro MF, Cabrera Cabrera JA: Obstructive
uropathy caused by retroperitoneal fibrosis secondary to an
aneurysm of the abdominal aorta.  Actas Urol Esp 2000,
24:764-766.
204. Breems DA, Haye H, van der MJ: The role of advanced athero-
sclerosis in idiopathic retroperitoneal fibrosis. Analysis of
nine cases.  Neth J Med 2000, 56:38-44.
205. Serra RM, Engle JE, Jones RE, Schoolwerth AC: Perianeurysmal
retroperitoneal fibrosis. An unusual cause of renal failure.
Am J Med 1980, 68:149-153.
206. Hautekeete ML, Babany G, Marcellin P, Gayno S, Palazzo E, Erlinger S,
Benhamou JP: Retroperitoneal fibrosis after surgery for aortic
aneurysm in a patient with periarteritis nodosa: successful
treatment with corticosteroids.  J Intern Med 1990, 228:533-536.
207. Izzedine H, Servais A, Launay-Vacher V, Deray G: Retroperitoneal
fibrosis due to Wegener's granulomatosis: a misdiagnosis as
tuberculosis.  Am J Med 2002, 113:164-166.
208. Regan F, Tran T, Crofton ME: Case report: idiopathic retroperi-
toneal fibrosis: an unusual cause of an ovarian mass.  Br J Radiol
1993, 66:558-560.
209. Tsai TC, Chang PY, Chen BF, Huang FY, Shih SL: Retroperitoneal
fibrosis and juvenile rheumatoid arthritis.  Pediatr Nephrol 1996,
10:208-209.
210. Stey C, Truninger K, Marti D, Vogt P, Medici TC: Bronchiolitis
obliterans organizing pneumonia associated with polymyal-
gia rheumatica.  Eur Respir J 1999, 13:926-929.
211. Bezza A, Maghraoui AE, Ghadouane M, Tabache F, Abouzahir A,
Abbar M, Ghafir D, Ohayon V, Archane MI: Idiopathic retroperi-
toneal fibrosis and ankylosing spondylitis. A new case report.
Joint Bone Spine 2002, 69:502-505.
212. Ewald EA, Gikas PW, Castor CW: Periarticular fibrosis associ-
ated with idiopathic retroperitoneal fibrosis.  J Rheumatol 1988,
15:1443-1446.
213. Sozay S, Bayramoglu M, Karatas M, Ozker R: Diffuse idiopathic
skeletal hyperostosis in a patient with idiopathic retroperito-
neal fibrosis: a case report.  Rheumatol Int 2002, 22:249-252.
214. Knoell KA, Hook M, Grice DP, Hendrix JD Jr: Dermatomyositis
associated with bronchiolitis obliterans organizing pneumo-
nia (BOOP).  J Am Acad Dermatol 1999, 40:328-330.
215. Fata F, Rathore R, Schiff C, Herzlich BC: Bronchiolitis obliterans
organizing pneumonia as the first manifestation of polymy-
ositis.  South Med J 1997, 90:227-230.
216. Mansell MA, Watts RW: Retroperitoneal fibrosis and sclero-
derma.  Postgrad Med J 1980, 56:730-733.
217. Okada H, Takahira S, Sugahara S, Nakamoto H, Suzuki H: Retroperi-
toneal fibrosis and systemic lupus erythematosus.  Nephrol
Dial Transplant 1999, 14:1300-1302.
218. Wallach PM, Flannery MT, Adelman HM, PowSang J, Saba H, Altus P,
Espinoza LR: Retroperitoneal fibrosis accompanying immune
thrombocytopenia.  Am J Hematol 1991, 37:204-205.
219. Nakamura A, Funatomi H, Katagiri A, Katayose K, Kitamura K, Seki
T, Yamamura F, Aoyagi Y, Nishida H, Mitamura K: A case of
autoimmune pancreatitis complicated with immune throm-
bocytopenia during maintenance therapy with prednisolone.
Dig Dis Sci 2003, 48:1968-1971.
220. Iwami S, Ryu T, Kasai S, Tokuda H, Saitoh T: Idiopathic interstitial
pneumonia with autoimmune hemolytic anemia.  Nippon
Naika Gakkai Zasshi 2003, 92:1079-1081.
221. Pineau BC, Pattee LP, McGuire S, Sekar A, Scully LJ: Unusual pres-
entation of primary sclerosing cholangitis.  Can J Gastroenterol
1997, 11:45-48.
222. Briffod M, Berlie J, Clavel B, Hebert H: Retroperitoneal malignant
xanthogranuloma (author's transl).  Sem Hop 1982, 58:113-119.
223. de Sa J, Pimentel J, Carvalho M, Evangelista P, Martins P: Spinal cord
compression secondary to idiopathic retroperitoneal fibro-
sis.  Neurosurgery 1990, 26:678-681.
224. Sevenet F, Capron-Chivrac D, Delcenserie R, Lelarge C, Delamarre J,
Capron JP: Idiopathic retroperitoneal fibrosis and primary bil-
iary cirrhosis. A new association?  Arch Intern Med 1985,
145:2124-2125.
225. Rozynek M: Mesenteric lipodystrophy as a variant of
Ormond's disease.  Patol Pol 1975, 26:525-528.
226. Verit A, Yeni E, Unal D, Kafali H, Ozturk A, Ozardali I: Idiopathic
retroperitoneal fibrosis mimicking a pelvic tumor: a case of
pericystitis plastica.  Yonsei Med J 2003, 44:548-550.
227. Haciyanli M, Erkan N, Elverdi B, Avci G, Fuzun M, Dicle O: Retro-
peritoneal fibrosis mimicking a rectal tumor: report of a
case.  Dis Colon Rectum 1998, 41:664-666.
228. Yamada H, Komatsu R, Nagae H, Fujioka Y, Fujita M: Idiopathic ret-
roperitoneal fibrosis with duodenal obstruction successfully
treated with corticosteroids.  Intern Med 1998, 37:592-598.
229. Jun BM, Lee EY, Yoon YJ, Kim EK, Ahn MS, Lee CK, Cho YS, Yoo B,
Moon HB: Retroperitoneal fibrosis with duodenal stenosis.  J
Korean Med Sci 2001, 16:371-374.
230. Realini S, Reiner M, Bernasconi S, Pedrinis E: Retroperitoneal
fibrosis and portal hypertension.  Schweiz Med Wochenschr 1993,
123:26-28.
231. Zabetakis PM, Novich RK, Matarese RA, Michelis MF: Idiopathic
retroperitoneal fibrosis: a systemic connective tissue dis-
ease?  J Urol 1979, 122:100-102.
232. Moroni G, Farricciotti A, Cappelletti M, Ponticelli C: Retroperito-
neal fibrosis and membranous nephropathy. Improvement
of both diseases after treatment with steroids and immuno-
suppressive agents.  Nephrol Dial Transplant 1999, 14:1303-1305.
233. Uchiyama-Tanaka Y, Mori Y, Kimura T, Sonomura K, Umemura S,
Kishimoto N, Nose A, Tokoro T, Kijima Y, Yamahara H, Nagata T,
Masaki H, Umeda Y, Okazaki K, Iwasaka T: Acute tubulointersti-
tial nephritis associated with autoimmune-related pancrea-
titis.  Am J Kidney Dis 2004, 43:e18-e25.
234. Nistal M, Paniagua R, Torres A, Hidalgo L, Regadera J: Idiopathic
peritesticular fibrosis associated with retroperitoneal fibro-
sis.  Eur Urol 1986, 12:64-68.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1741-7015/4/23/prepub